Skip to main content

Advertisement

SpringerLink
Log in

Associations of Serum Cytokine Receptor Levels with Melancholia, Staging of Illness, Depressive and Manic Phases, and Severity of Depression in Bipolar Disorder

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

To examine cytokine receptor biomarkers in bipolar disorder (BD), we recruited 133 well-phenotyped BD patients and 50 normal controls and measured serum levels of soluble interleukin 1 receptor antagonist (sIL-1RA), soluble interleukin-2 receptor (sIL-2R), sIL-6R, and tumor necrosis factor receptor 60 and 80 kDa (sTNFR60/80). sIL-1RA and sTNFR80 are significantly higher in BD than in controls and sTNFR80 and higher in melancholic than in non-melancholic patients and controls. Kapczinski’s stages 3 + 4 are characterized by lowered sIL-2R and increased sTNFR80 levels. Acute phase depression is characterized by increased sTNFR80 levels as compared with controls, manic, and euthymic patients. Both sTNFR60 and sTNFR80 levels are significantly and positively related with severity of depression but not mania. Logistic regression analysis showed that the significant predictors for BD are increased sIL-1RA levels, nicotine dependence and a family history of depression and alcoholism. The risk factors for stages 3 + 4 are lowered sIL-2R levels and nicotine dependence. Melancholia is predicted by higher sTNFR80 levels and female sex. Severity of depression is predicted by female sex, nicotine dependence, and increased sTNFR60 and sTNFR80 levels. Cell-mediated immunity is activated during a current episode of depression but not (hypo)mania or the euthymic state. There are no associations between the biomarkers and age at onset, duration of illness, severity of mania, bipolar (BP)2 or BP1 subtypes, rapid cycling, atypical depression, psychotic or suicidal symptoms, and a family history of psychiatric disease. The results show that increased sIL-1RA may be a trait marker of BD, increased sTNFR80 a state marker of the depressive phase, especially melancholia, while lower sIL-2R but higher sTNFR80 may be staging biomarkers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R (1995) Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 34(4):301–309

    Article  CAS  PubMed  Google Scholar 

  2. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY (1995) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29(2):141–152

    Article  CAS  PubMed  Google Scholar 

  3. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpé S (1997) Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 66(1):1–11

    Article  CAS  PubMed  Google Scholar 

  4. Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Raus J (1991) Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 84(4):379–386

    Article  CAS  PubMed  Google Scholar 

  5. Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C, de Jonckheere C, Minner B et al (1992) Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 22(1):45–53

  6. Maes M, Scharpe S, Bosmans E, Vandewoude M, Suy E, Uyttenbroeck W, Cooreman W, Vandervorst C et al (1992) Disturbances in acute phase plasma proteins during melancholia: additional evidence for the presence of an inflammatory process during that illness. Prog Neuro-Psychopharmacol Biol Psychiatry 16(4):501–515

  7. Rapaport MH (1994) Immune parameters in euthymic bipolar patients and normal volunteers. J Affect Disord 32(3):149–156

    Article  CAS  PubMed  Google Scholar 

  8. O’Brien SM, Scully P, Scott LV, Dinan TG (2006) Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 90(2–3):263–267

    Article  PubMed  Google Scholar 

  9. Kim YK, Jung HG, Myint AM, Kim H, Park SH (2007) Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 104(1–3):91–95

    Article  CAS  PubMed  Google Scholar 

  10. Barbosa IG, Huguet RB, Mendonça VA, Sousa LP, Neves FS, Bauer ME, Teixeira AL (2011) Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 261(2):139–143

    Article  PubMed  Google Scholar 

  11. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M (2013) Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 74(1):15–25

    Article  CAS  PubMed  Google Scholar 

  12. Munkholm K, Braüner JV, Kessing LV, Vinberg M (2013) Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 47(9):1119–1133

    Article  PubMed  Google Scholar 

  13. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS et al (2011) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35(3):804–817

  14. Anderson G, Maes M (2015) Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites. Curr Psychiatry Rep 17(2):8

    Article  PubMed  Google Scholar 

  15. Ortiz-Domínguez A, Hernández ME, Berlanga C, Gutiérrez-Mora D, Moreno J, Heinze G, Pavón L (2007) Immune variations in bipolar disorder: phasic differences. Bipolar Disord 9(6):596–602

    Article  PubMed  Google Scholar 

  16. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant’anna M, Mascarenhas M, Escosteguy Vargas A, Chies JA, Kapczinski F (2009) Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 116(3):214–217

    Article  CAS  PubMed  Google Scholar 

  17. Doganavsargil-Baysal O, Cinemre B, Aksoy UM, Akbas H, Metin O, Fettahoglu C, Gokmen Z, Davran F (2013) Levels of TNF-α, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol 28(2):160–167

    Article  CAS  PubMed  Google Scholar 

  18. Bai YM, Su TP, Tsai SJ, Wen-Fei C, Li CT, Pei-Chi T, Mu-Hong C (2014) Comparison of inflammatory cytokine levels among type I/type II and manic /hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord 166:187–192

    Article  CAS  PubMed  Google Scholar 

  19. Monfrim X, Gazal M, De Leon PB, Quevedo L, Souza LD, Jansen K, Oses JP, Pinheiro RT et al (2014) Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropin-releasing hormone and interleukin-1β? Bipolar Disord 16(7):741–747

  20. Rafiei A, Hosseini SH, Taheri M, Hosseni-khah Z, Hajilooi M, Mazaheri Z (2013) Influence of IL-1RN intron 2 variable number of tandem repeats (VNTR) polymorphism on bipolar disorder. Neuropsychobiology 67(2):116–121

    Article  CAS  PubMed  Google Scholar 

  21. Grande I, Magalhães PV, Chendo I, Stertz L, Panizutti B, Colpo GD, Rosa AR, Gama CS et al (2014) Staging bipolar disorder: clinical, biochemical, and functional correlates. Acta Psychiatr Scand 129(6):437–444

  22. Hope S, Ueland T, Steen NE, Dieset I, Lorentzen S, Berg AO, Agartz I, Aukrust P et al (2013) Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res 145(1–3):36–42

  23. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (4th ed., text rev.). doi:10.1176/appi.books.9780890423349

  24. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389

    Article  CAS  PubMed  Google Scholar 

  25. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435

    Article  CAS  PubMed  Google Scholar 

  27. Kapczinski F, Dias VV, Kauer-Sant’Anna M, Frey BN, Grassi-Oliveira R, Colom F, Berk M (2009) Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 9:957–966

    Article  PubMed  Google Scholar 

  28. Kapczinski F, Dias VV, Kauer-Sant’Anna M, Brietzke E, Vázquez GH, Vieta E, Berk M (2009) The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 33:1366–1371

    Article  CAS  Google Scholar 

  29. Powell TR, McGuffin P, D’Souza UM, Cohen-Woods S, Hosang GM, Martin C, Matthews K, Day RK et al (2014) Putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients. PLoS One 9(3):e91076

  30. Pandey GN, Ren X, Rizavi HS, Zhang H (2015) Abnormal gene expression of proinflammatory cytokines and their receptors in the lymphocytes of patients with bipolar disorder. Bipolar Disord. doi:10.1111/bdi.12320

    PubMed Central  Google Scholar 

  31. Karlović D, Serretti A, Vrkić N, Martinac M, Marčinko D (2012) Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res 198(1):74–80

    Article  PubMed  Google Scholar 

  32. Celik C, Erdem M, Cayci T, Ozdemir B, Ozgur Akgul E, Kurt YG, Yaman H, Isintas M et al (2010) The association between serum levels of neopterin and number of depressive episodes of major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 34(2):372–375

  33. Maes M, Mihaylova I, Kubera M, Ringel K (2012) Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 36(1):169–175

    Article  Google Scholar 

  34. Nunes SO, Vargas HO, Prado E, Barbosa DS, de Melo LP, Moylan S, Dodd S, Berk M (2013) The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci Biobehav Rev 37(8):1336–1345

    Article  CAS  PubMed  Google Scholar 

  35. Vargas HO, Nunes SO, Pizzo de Castro M, Bortolasci CC, Sabbatini Barbosa D, Kaminami Morimoto H, Venugopal K, Dodd S et al (2013) Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J Affect Disord 150(3):923–930

Download references

Acknowledgments

None.

Author information

Authors and Affiliations

  1. Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Kopernika 21a, 31-501, Krakow, Poland

    Marcin Siwek, Krzysztof Styczeń & Dominika Dudek

  2. Laboratory of Trace Elements Neurobiology, Institute of Pharmacology PAS, Smetna 12, 31-343, Krakow, Poland

    Magdalena Sowa-Kućma, Paulina Misztak, Bernadeta Szewczyk & Gabriel Nowak

  3. Chair of Pharmacobiology, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland

    Paulina Misztak & Gabriel Nowak

  4. Department of Drug Management, Jagiellonian University Medical College, Grzegórzecka 20, 31-531, Krakow, Poland

    Rafał J. Nowak

  5. Department of Adult Psychiatry, Poznań University of Medical Sciences, Szpitalna 27/33, 60-572, Poznań, Poland

    Janusz K. Rybakowski

  6. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

    Michael Maes

  7. IMPACT Strategic Research Centre, Deakin University, School of Medicine and Barwon Health, Geelong, VIC, Australia

    Michael Maes

  8. Health Sciences Postgraduate Program, State University of Londrina, Londrina, Paraná, Brazil

    Michael Maes

  9. Revitalis, Waalre, The Netherlands

    Michael Maes

  10. Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria

    Michael Maes

Authors
  1. Marcin Siwek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Magdalena Sowa-Kućma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Krzysztof Styczeń
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paulina Misztak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rafał J. Nowak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bernadeta Szewczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dominika Dudek
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Janusz K. Rybakowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gabriel Nowak
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michael Maes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Maes.

Ethics declarations

The study was approved by the bioethical committee of the Jagiellonian University, Krakow, Poland, and all subjects gave written informed consent prior to participating in this study.

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding

This study was financially supported by grant POIG. 01.01.02-12-004/09-00 (Depression-Mechanisms-Therapy) cofinanced by the European Union from the European Regional Development Fund.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Siwek, M., Sowa-Kućma, M., Styczeń, K. et al. Associations of Serum Cytokine Receptor Levels with Melancholia, Staging of Illness, Depressive and Manic Phases, and Severity of Depression in Bipolar Disorder. Mol Neurobiol 54, 5883–5893 (2017). https://doi.org/10.1007/s12035-016-0124-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-016-0124-8

Keywords

Search

Navigation